<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212913</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_04867</org_study_id>
    <secondary_id>U1111-1117-2786</secondary_id>
    <nct_id>NCT01212913</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)</brief_title>
  <acronym>B to B</acronym>
  <official_title>Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the non-inferiority of hemoglobin A1c (HbA1c) control at six months between
      the basal plus one and the biphasic insulin regimen.

      Secondary Objective:

      To demonstrate favorable outcome for basal plus over biphasic insulin when it comes to
      comparing when both hemoglobin A1c (HbA1c) target goal achievement and non-hypoglycemic event
      is taken into account.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin A1c level (HbA1c)</measure>
    <time_frame>At 6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hypoglycemic events (total, severe, nocturnal)</measure>
    <time_frame>from baseline to the study endpoint (over 6 months of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HbA1c &lt; 7%</measure>
    <time_frame>from baseline to the study endpoint (over 6 months of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>from baseline to the study endpoint (over 6 months of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Oxidative Stress (ROS) level changes</measure>
    <time_frame>from baseline to the study endpoint (over 6 months of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>from baseline to the study endpoint (over 6 months of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring System (CGMS) data</measure>
    <time_frame>at baseline, 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>group 1: Basal plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2: Biphasic insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL &lt; Pre-meal blood glucose (dinner and breakfast).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily</description>
    <arm_group_label>group 1: Basal plus</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily</description>
    <arm_group_label>group 1: Basal plus</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily</description>
    <arm_group_label>group 2: Biphasic insulin</arm_group_label>
    <other_name>NovoMix 30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Sub-optimally controlled Type 2 Diabetes Mellitus (T2DM) patients treated with insulin
             glargine for a minimum of 3 months:

               -  Sub-optimal: HbA1c level &gt;7% and fasting blood glucose &lt;130mg/dL

          2. Male or Female ≥18 years old

          3. Body Mass Index (BMI) &lt;40

          4. 10% ≥HbA1c ≥7%

          5. If taking Oral anti-diabetics (OADs), must be on stable dose for at least 1 months

          6. Patients willing to sign data release consent form

        Exclusion criteria:

          1. Diabetes other than T2DM

          2. Enrolled in other clinical trials

          3. Previous treatment with an insulin other than insulin glargine

          4. Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or with Di Peptidyl
             Peptidase 4 (DPP-IV) inhibitors

          5. Pregnant or lactating women

          6. Contraindicated to Lantus (insulin glargine) / Apidra (insulin glulisine) / Novomix 30
             (insulin aspart)

          7. Treatment with systemic corticoid steroids within the last 3 months prior to study
             enter

          8. Treatment with any investigational product within the last 3 months prior to study
             entry

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2010</study_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

